Select therapeutic use:

Miscellaneous Ob/Gyn conditions:

Indications for ZULRESSO:

Treatment of postpartum depression.

Adult:

Give as a continuous IV infusion over 60hrs (2.5 days). 0–4hrs: initially 30mcg/kg/hr; 4–24hrs: increase to 60mcg/kg/hr; 24–52hrs: increase to 90mcg/kg/hr (reduction to 60mcg/kg/hr may be considered if not tolerated at this time period); 52–56hrs: decrease to 60mcg/kg/hr; 56–60hrs: decrease to 30mcg/kg/hr. ESRD (eGFR <15mL/min/1.73m2): avoid.

Children:

Not established.

Boxed Warning:

Excessive sedation and sudden loss of consciousness.

Warnings/Precautions:

Risk of excessive sedation or sudden loss of consciousness during therapy; must be monitored with continuous pulse oximetry. During therapy, monitor for sedative effects every 2hrs during non-sleep periods. Discontinue infusion if signs/symptoms of excessive sedation; may resume after resolution at the same or lower dose. Suicidal thoughts and behaviors. Consider changing regimen or discontinuing therapy if depression worsens or persists. ESRD: see Adults. Pregnancy. Nursing mothers.

Pharmacologic Class:

GABAA receptor modulator.

Interactions:

May increase the likelihood or severity of sedation with concomitant antidepressants or other CNS depressants (eg, opioids, benzodiazepines, alcohol).

Adverse Reactions:

Sedation/somnolence, dry mouth, loss of consciousness, flushing/hot flush.

Note:

Register pregnant patients exposed to antidepressants by calling the National Pregnancy Registry for Antidepressants at (844) 405-6185.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Pricing for ZULRESSO

5mg/ml vial (Qty: 1)
Appx. price $378
GoodRx

Mood disorders:

Indications for ZULRESSO:

Treatment of postpartum depression.

Adult:

Give as a continuous IV infusion over 60hrs (2.5 days). 0–4hrs: initially 30mcg/kg/hr; 4–24hrs: increase to 60mcg/kg/hr; 24–52hrs: increase to 90mcg/kg/hr (reduction to 60mcg/kg/hr may be considered if not tolerated at this time period); 52–56hrs: decrease to 60mcg/kg/hr; 56–60hrs: decrease to 30mcg/kg/hr. ESRD (eGFR <15mL/min/1.73m2): avoid.

Children:

Not established.

Boxed Warning:

Excessive sedation and sudden loss of consciousness.

Warnings/Precautions:

Risk of excessive sedation or sudden loss of consciousness during therapy; must be monitored with continuous pulse oximetry. During therapy, monitor for sedative effects every 2hrs during non-sleep periods. Discontinue infusion if signs/symptoms of excessive sedation; may resume after resolution at the same or lower dose. Suicidal thoughts and behaviors. Consider changing regimen or discontinuing therapy if depression worsens or persists. ESRD: see Adults. Pregnancy. Nursing mothers.

Pharmacologic Class:

GABAA receptor modulator.

Interactions:

May increase the likelihood or severity of sedation with concomitant antidepressants or other CNS depressants (eg, opioids, benzodiazepines, alcohol).

Adverse Reactions:

Sedation/somnolence, dry mouth, loss of consciousness, flushing/hot flush.

Note:

Register pregnant patients exposed to antidepressants by calling the National Pregnancy Registry for Antidepressants at (844) 405-6185.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-dose vial—1

Pricing for ZULRESSO

5mg/ml vial (Qty: 1)
Appx. price $378
GoodRx